Ortho Regenerative Technologies Inc. is a clinical stage orthobiologics company dedicated to developing novel therapeutic soft tissue repair technologies to dramatically improve the success rate of orthopedic and sports medicine surgeries. Our proprietary RESTORE technology platform is a mucoadhesive Chitosan-based biopolymer matrix that delivers biologics such as Platelet-Rich Plasma (PRP) to augment and guide the regeneration of new tissue in various musculoskeletal conditions. Ortho-R ®, our lead Chitosan-PRP hybrid drug/biologic implant combination product, is designed to increase the healing rates of occupational and sports-related injuries to tendons, meniscus, and ligaments. Other formulations are being developed for cartilage repair, bone void filling, and osteoarthritis treatment. The ORTHO-R® implant can be directly delivered into the site of injury by a surgeon during a routine arthroscopic operative procedure without significantly extending the time of the surgery and without further intervention. Unlike other natural biopolymer matrices, the ORTHO-R® chitosan molecules are poly-cationic. They are mucoadhesive to the negatively charged soft tissues of the human body. Characteristics related to the electrostatic binding of the ORTHO-R Chitosan-PRP combination product used as an adjunct to standard of care surgery result in modification of cell function. They inhibit blood clot retraction and extend the release/expression of growth factors from platelets’ granules, compared to PRP alone, which the U.S. FDA justified for classifying the ORTHO-R® biopolymer formulation as a drug. It is, therefore, a perfect combination matrix system for orthobiologics such as PRP, used in various musculoskeletal injury conditions. With its mucoadhesive feature, it offers the unique benefit of significantly increasing the in-situ residency time of PRP, from less than 24 hours for PRP alone to up to 6 weeks for ORTHO-R® chitosan-PRP drug/biologic combination product.